The New England Journal of Medicine Publishes Landmark Studies of Noxafil in the Prevention of Invasive Fungal Infections - a Leading Cause of Death Among Immunocompromised Patients
Posted on: Wednesday, 24 January 2007, 12:01 CST
ADDITIONAL RESOURCES: Video, hard copy requests, contact information and more available at: http://www.prnewswire.com/broadcast/26505/consumer.html
THIS IS A MULTIVU SPECIAL REPORT BROUGHT TO YOU BY SCHERING-PLOUGH CORPORATION. EACH YEAR IN THE UNITED STATES MORE THAN 1.3 MILLION HOSPITAL PATIENTS ARE AFFECTED BY INVASIVE FUNGAL INFECTIONS OR IFIS. ONCE IFIS ARE ESTABLISHED IN HIGH-RISK PATIENTS, SUCH AS STEM CELL TRANSPLANT RECIPIENTS OR NEUTROPENIC CHEMOTHERAPY PATIENTS, THEY ARE EXTREMELY DIFFICULT TO TREAT, WITH MORTALITY RATES RANGING FROM 50 TO 90 PERCENT.
ACCORDING TO TWO LANDMARK STUDIES PUBLISHED RECENTLY IN THE NEW ENGLAND JOURNAL OF MEDICINE, NOXAFIL - A POTENT NEW AGENT TO PREVENT IFIS -- SIGNIFICANTLY REDUCED THE NUMBER OF DEATHS DUE TO FUNGAL INFECTIONS COMPARED TO OTHER ANTIFUNGALS.
ANDREW J. ULLMANN, M.D., LEAD AUTHOR OF ONE OF THE PUBLISHED STUDIES:
"These studies demonstrate that posaconazole prophylaxis provides effective, well-tolerated, preventive therapy, allowing physicians to focus on treating their patient's underlying disease."
NOXAFIL IS THE FIRST AND ONLY ANTIFUNGAL AGENT APPROVED TO PREVENT THE TWO MOST COMMON TYPES OF IFIS. FOR MORE INFORMATION, VISIT, SCHERING-PLOUGH.COM.
I'M CHRISTIANE ARBESU.
AUDIO PROVIDED BY: Schering-Plough Corporation
Audio: http://www.prnewswire.com/broadcast/26505/consumer.html
Schering-Plough Corporation
CONTACT: FOR STORY INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313, EXT. 3 OR EMAIL RADIO@MULTIVU.COM
Web site: http://www.schering-plough.com/
Source: PRNewswire
Related Articles
- Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
- Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
- Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings From Previous Phase II Study
- Schering-Plough Initiates Pivotal HIV Drug Studies
- The Immune Response Corporation Injects First Patient in Trial of NeuroVax(TM) for Treatment of Multiple Sclerosis
- Schering-Plough Infectious Drug Effective in Studies
- Schering-Plough Begins Phase IV Hepatitis Study
- Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients With Recurrent Hepatitis C
- Study: Patients Shouldn't Give Up on Banishing Depression
- Cyberonics Announces Closure of Investigational Device Exemption (IDE) for Treatment-Resistant Depression (TRD), Lifetime Reimbursement Guarantee for All TRD IDE Study Patients and $15 Million TRD Indigent Care Program
 |
 |
User Comments (0)
RSS Feeds